Brief: Larimar Therapeutics Announces FDA Recommendations On Safety Database
23/06/2025 12:07
June 23 (Reuters) - Larimar Therapeutics Inc LRMR.O: LARIMAR THERAPEUTICS ANNOUNCES FDA RECOMMENDATIONS ON SAFETY DATABASE, AND OTHER DETAILS OF NOMLABOFUSP BLA SUBMISSION FOR FRIEDREICH’S ATAXIA PROGRAM LARIMAR THERAPEUTICS INC - BLA SUBMISSION FOR ACCELERATED APPROVAL PLANNED IN Q2 2026 LARIMAR THERAPEUTICS INC - OLE DATA EXPECTED IN SEPTEMBER 2025 FROM 30-40 PARTICIPANTS LARIMAR THERAPEUTICS INC - ADOLESCENT PK RUN-IN DATA EXPECTED IN SEPTEMBER 2025 Source text: ID:nGNX4TyBGr Further company coverage: LRMR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update